RayzeBio $358 million IPO
The stock is listed on the Nasdaq Global Market
Davis Polk advised the joint book-running managers in connection with the upsized initial public offering of 19,869,240 shares of common stock of RayzeBio, Inc., of which 18,706,240 shares were issued and sold by the company and 1,163,000 shares were sold by the selling stockholder. The shares sold include 2,591,640 shares sold pursuant to the underwriters’ over-allotment option. The common stock is listed on the Nasdaq Global Market under the symbol “RYZB.”
RayzeBio is a targeted radiopharmaceutical company developing an innovative pipeline against validated solid tumor targets.
The Davis Polk corporate team included partner Alan F. Denenberg and associates Beth LeBow and Eddie Magana. Partner David R. Bauer and associates Alison T. Chin and Lauren Nathan provided intellectual property advice. The tax team included partner Mario J. Verdolini and associate Charles Collier. Counsel Marcie A. Goldstein provided FINRA advice. Members of the Davis Polk team are based in the Northern California and New York offices.